Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Australia / NCT03193151
Recruiting Observational

Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation

NCT03193151 · tracked via the Priya Life Science Australia tracker
Sponsor
University of Alberta
Phase
Observational
Started
2017-12-19
Last updated
2026-06-04

Condition(s) studied

Liver Dysfunction

Investigational drug(s) / intervention(s)

liver biopsy

liver biopsy: 5 mm fragment of liver transplant biopsy taken for clinical indication

Study summary

INTERLIVER is a prospective observational study of the relationship of the molecular phenotype of 300 liver transplant biopsies to the histologic phenotype and the clinical features and outcomes. A segment of a biopsy performed as standard-of-care for indications, or by center protocol, will be used for gene expression study.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * biopsy for clinical indications Exclusion Criteria: * no consent, pregnant women

Primary outcome measure(s)

  • Assign molecular scores (probability) of T cell mediated rejection, antibody mediated rejection in liver transplant biopsies, in a reference set of 100 biopsies — two years
    Based on the reference set, create molecular classifier that predicts antibody mediated and T cell mediated rejection for next 200 biopsies

Trial sites (15)

FacilityCityRegionStatus
University of California San Francisco, Transplant Research Unit San Francisco California Completed
Northwestern Memorial Hospital Chicago Illinois Completed
University of Maryland School of Medicine Baltimore Maryland Completed
Henry Ford Transplant Institute Detroit Michigan Recruiting
Vanderbilt University Medical Center, Vanderbilt Transplant Center Nashville Tennessee Withdrawn
Baylor University Medical Center, Annette C. and Harold C. Simmons Transplant Institute Dallas Texas Completed
Transplant Surgery, VCU Medical Center Richmond Virginia Completed
Division of Transplant Surgery, University of Washington Seattle Washington Completed
Centenary Institute of Cancer Medicine & Cell Biology, Royal Prince Alfred Hospital Camperdown Australia Completed
University of Alberta, Laboratory Medicine and Pathology Edmonton Alberta Completed
Dep. of Nephrology, Transplantation & Internal Med., Samodzielny Publiczny Szpital Kliniczny im. A. Mieleckiego Katowice Poland Completed
Independent Public Composite Regional Hospital Szczecin Poland Completed
Warsaw Medical University, Jesus the Child Clinical Hospital Warsaw Poland Completed
Warsaw Medical University, Independent Public Clinical Hospital Warsaw Poland Completed
Institute for Liver Science, King's College London London United Kingdom Completed

More University of Alberta trials in Australia

Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation Recruiting
Trifecta-Heart cfDNA-MMDx Study Recruiting
Trifecta-Lung cfDNA-MMDx Study Recruiting
Lumbar Brace Deployment in the Emergency Department for Benign Low Back Pain Recruiting
Trifecta-Kidney cfDNA-MMDx Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03193151 on ClinicalTrials.gov ↗ ← All trials in Australia